Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$883.44 USD

883.44
282,448

-2.11 (-0.24%)

Updated Oct 4, 2024 10:18 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

Glaxo (GSK), Vir Intramuscular Sotrovimab Meets Study Endpoint

Glaxo (GSK) and Vir announce non-inferiority of intramuscular administration of sotrovimab compared to intravenous administration in reducing hospitalization or death as an early treatment of mild-to-moderate COVID-19.

Biogen (BIIB) Up on New Data From Phase III Studies on Aduhelm

Biogen's (BIIB) Aduhelm significantly lowers plasma p-tau-181, a pathological hallmark of Alzheimer's disease, in phase III studies.

Merck (MRK) Inks $1.2B COVID-19 Pill Supply Deal With Japan

Japan's government is set to purchase 1.6 million courses of Merck's (MRK) oral pill for COVID-19, molnupiravir, if approved or authorized.

Biohaven (BHVN) Misses on Q3 Earnings, Inks $1.24B Pfizer Deal

Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. The company signs an agreement with Pfizer, granting the latter ex-U.S. marketing rights to Nurtec ODT.

Radius (RDUS) Q3 Loss Wider Than Expected, Stock Declines

Radius (RDUS) reports a year-over-year wider Q3 loss and misses on sales. The company also lowers guidance for lead drug Tymlos.

Pfizer (PFE) COVID Pill Shows Strong Efficacy, Stock Rallies

Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially

Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar?

Style Box ETF report for USMV

Nektar (NKTR) Q3 Earnings Top, Pipeline Remains On Track

Nektar (NKTR) reports mixed third-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.

United Therapeutics (UTHR) Q3 Earnings & Sales Beat, Stock Up

United Therapeutics (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.

Novo Nordisk's (NVO) Q3 Earnings and Sales Beat Estimates

Novo Nordisk (NVO) reports better-than-expected results for Q3. Sales are aided by growth in Diabetes and Obesity Care owing to higher GLP-1 revenues.

PFE vs. LLY: Which Stock Should Value Investors Buy Now?

PFE vs. LLY: Which Stock Is the Better Value Option?

Amgen (AMGN) Q3 Earnings Top, Sales View Tightened, Stock Down

Amgen (AMGN) beats Q3 estimates for both earnings and sales. It lowers the upper end of the sales guidance for 2021 while raising the earnings range.

Incyte (INCY) Q3 Earnings & Sales Beat, Royalty Revenues Grow

Incyte (INCY) beats earnings and sales estimates in the third quarter on higher royalty revenues and increased Jakafi sales.

The Zacks Analyst Blog Highlights: Alphabet, Eli Lilly, Sony, American Express and Southern Company

The Zacks Analyst Blog Highlights: Alphabet, Eli Lilly, Sony, American Express and Southern Company

Sheraz Mian headshot

Top Research Reports for Alphabet, Eli Lilly & Sony

Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Eli Lilly and Company (LLY), and Sony Group Corporation (SONY).

Kinjel Shah headshot

Pharma Stock Roundup: Big Pharma Q3 Results, FDA Panel's Vote for PFE COVID Jab

Several big drugmakers announce third-quarter 2021 earnings. An FDA panel votes in favor of Pfizer's (PFE) COVID-19 vaccine for use in kids 5 to 11 years of age.

Sweta Killa headshot

Healthcare ETFs in Focus as Q3 Earnings Unfold

The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.

Stock Market News for Oct 27, 2021

U.S. stocks continued their winning streak on Tuesday, with the Dow and the S&P 500 closing at record highs for the second straight day as investors digested a slew of earnings reports from some of biggest American corporations.

AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?

AbbVie's (ABBV) third-quarter results are expected to reflect the impact of a strong recovery in demand for new drugs. Investors are likely to focus on any update related to guidance.

Eli Lilly (LLY) Q3 Earnings Miss, COVID Drugs Drive Sales

Eli Lilly (LLY) reports mixed third-quarter results and raises its 2021 sales forecast.

Mark Vickery headshot

Home Prices Stay "Lofty;" UPS Beats, Lilly Mixed

The Case-Shiller Home Price Index for August came in at +19.8%, right in-line with what analysts were looking for.

Q3 Earnings Season in Full Swing

Q3 Earnings Season in Full Swing

Eli Lilly (LLY) Misses Q3 Earnings Estimates

Lilly (LLY) delivered earnings and revenue surprises of -2.02% and 1.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?